• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Immunovant, Inc. - Common Stock (NQ:IMVT)

    40.92 +0.61 (+1.51%)
    Streaming Delayed Price Updated: 2:25 PM EDT, Jul 9, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 510,787
    Open 40.36
    Bid (Size) 40.90 (300)
    Ask (Size) 40.94 (200)
    Prev. Close 40.31
    Today's Range 40.36 - 41.23
    52wk Range 14.32 - 40.77
    Shares Outstanding 114,998,871
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million ↗
    Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on metabolic and pulmonary conditions. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter ↗
    This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors. 
    Via The Motley Fool
    Topics Regulatory Compliance

    Performance

    YTD
    +57.9%
    +57.9%
    1 Month
    +32.9%
    +32.9%
    3 Month
    +65.5%
    +65.5%
    6 Month
    +53.1%
    +53.1%
    1 Year
    +142.3%
    +142.3%

    More News

    Read More
    News headline image
    What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    Immunovant Inc (NASDAQ:IMVT) Surges 26% Pre-Market on Strong IMVT-1402 Clinical Data Despite Wider Q4 Loss ↗
    Via Chartmill
    News headline image
    Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally ↗
    Via The Motley Fool
    News headline image
    These Analysts Increase Their Forecasts On Immunovant After Q4 Results ↗
    Via Benzinga
    Top movers in Wednesday's session ↗
    Via Chartmill
    News headline image
    Immunovant Stock Surges Despite Disappointing Earnings Miss ↗
    Via Benzinga
    Keep an eye on the top gainers and losers in Wednesday's session. ↗
    Via Chartmill
    Traders are paying attention to the gapping stocks in Wednesday's session. ↗
    Via Chartmill
    News headline image
    Immunovant Q4 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    Stay updated with the stocks that are on the move in today's pre-market session. ↗
    Via Chartmill
    News headline image
    Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? ↗
    Via The Motley Fool
    News headline image
    Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy? ↗
    Via The Motley Fool
    Topics ETFs Regulatory Compliance
    News headline image
    Amgen’s Subcutaneous TEPEZZA Data Sets New Gold Standard for Thyroid Eye Disease Treatment
    Via MarketMinute
    News headline image
    Roivant and Immunovant Solidify Market Leadership as Brepocitinib and FcRn Programs Hit Critical Clinical Milestones
    Via MarketMinute
    Topics Intellectual Property
    News headline image
    A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you? ↗
    Via The Motley Fool
    News headline image
    Complementing the Future: A Deep Dive into Dianthus Therapeutics (DNTH) After Its Phase 3 Breakthrough
    Via Finterra
    Topics Economy
    News headline image
    Air Taxi Stock Archer Aviation Draws $22.5 Million Institutional Buy. Here's What Investors Should Know ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish ↗
    Via The Motley Fool
    News headline image
    Truth Social Stock Down 50% as One Investor Sells Off Nearly 800,000 Shares ↗
    Via The Motley Fool
    Topics Government
    News headline image
    Argenx (ARGX) 2026 Feature: The Anatomy of a Biotech Powerhouse Transitioning to Profitability
    Via Finterra
    Topics Earnings Economy Intellectual Property
    News headline image
    Immunovant (IMVT) Q2 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model
    Via Finterra
    Topics ETFs Economy Initial Public Offering

    Frequently Asked Questions

    Is Immunovant, Inc. - Common Stock publicly traded?
    Yes, Immunovant, Inc. - Common Stock is publicly traded.
    What exchange does Immunovant, Inc. - Common Stock trade on?
    Immunovant, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Immunovant, Inc. - Common Stock?
    The ticker symbol for Immunovant, Inc. - Common Stock is IMVT on the Nasdaq Stock Market
    What is the current price of Immunovant, Inc. - Common Stock?
    The current price of Immunovant, Inc. - Common Stock is 40.92
    When was Immunovant, Inc. - Common Stock last traded?
    The last trade of Immunovant, Inc. - Common Stock was at 07/09/26 02:25 PM ET
    What is the market capitalization of Immunovant, Inc. - Common Stock?
    The market capitalization of Immunovant, Inc. - Common Stock is 4.71B
    How many shares of Immunovant, Inc. - Common Stock are outstanding?
    Immunovant, Inc. - Common Stock has 5B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.